To include your compound in the COVID-19 Resource Center, submit it here.

ALN-AAT: Development discontinued

Alnylam will discontinue development of ALN-AAT after interim data from a single-blind, U.K. Phase I/II trial in 26 healthy volunteers showed that

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE